Cancer: is a disease in which abnormal cells divide uncontrollably and destroy body tissue. Cancerous tumors are malignant, which means they can spread into, or invade, nearby tissues.
Uncovering the genetic lesions underpinning cancer through genomic profiling in a clinical setting could provide insights into possible treatment options for oncologists and their patients. N...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
When the BCR/ABL1 fusion protein was identified in chronic myelogenous leukemia and the JAK2 V617F mutation was identified in patients with other myeloproliferative neoplasms (MPNs) such as p...
Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq).Many analyses, such as...
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection and molecular monitoring. Join u...
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...
Patient-derived xenograft (PDX) models can recapitulate patient tumor histopathology, mutational status, gene expression patterns, and drug response with remarkable fidelity. At The Jackson L...
Human malignant glioma is a uniformly fatal disease, causing over 14,000 deaths in the US this year. Adults diagnosed with malignant brain tumors have a median survival of approximately 15 mo...
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...
DNASTAR offers an integrated suite of software for assembling and analyzing sequence data from all major next-generation sequencing platforms. The software supports a variety of key workflows...
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...
Circulating miRNAs have great potential as biomarkers due to their aberrant expression in cancer and other diseases. However, miRNAs from body fluids are hard to obtain in amounts sufficient...
Post-translational methylations play central roles in epigenetic gene regulation pathways that are central to stem cell regulation. Lysine methylations are turn-on switches for hundreds of di...
Although robust and clinically meaningful biomarkers are key to achieving the current vision for precision (molecularly based), cancer medicine (patient stratification, early diagnosis, drug...
The eukaryotic translation initiation factor eIF4E is an oncogene elevated in an estimated 30% of cancers. The traditional view is that eIF4E drives proliferation and survival by increasing t...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role...
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
Protein-protein interactions and allosterically regulated enzymes have been challenging but important targets for probe- and drug discovery. We and others have found that fragment-based lead...
Uncovering the genetic lesions underpinning cancer through genomic profiling in a clinical setting could provide insights into possible treatment options for oncologists and their patients. N...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
When the BCR/ABL1 fusion protein was identified in chronic myelogenous leukemia and the JAK2 V617F mutation was identified in patients with other myeloproliferative neoplasms (MPNs) such as p...
Cancer research is being revolutionized by targeted gene panels, whole exome sequencing (WES), whole genome sequencing (WGS), and transcriptome sequencing (RNA-Seq).Many analyses, such as...
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection and molecular monitoring. Join u...
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...
Patient-derived xenograft (PDX) models can recapitulate patient tumor histopathology, mutational status, gene expression patterns, and drug response with remarkable fidelity. At The Jackson L...
Human malignant glioma is a uniformly fatal disease, causing over 14,000 deaths in the US this year. Adults diagnosed with malignant brain tumors have a median survival of approximately 15 mo...
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...
DNASTAR offers an integrated suite of software for assembling and analyzing sequence data from all major next-generation sequencing platforms. The software supports a variety of key workflows...
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...
Circulating miRNAs have great potential as biomarkers due to their aberrant expression in cancer and other diseases. However, miRNAs from body fluids are hard to obtain in amounts sufficient...
Post-translational methylations play central roles in epigenetic gene regulation pathways that are central to stem cell regulation. Lysine methylations are turn-on switches for hundreds of di...
Although robust and clinically meaningful biomarkers are key to achieving the current vision for precision (molecularly based), cancer medicine (patient stratification, early diagnosis, drug...
The eukaryotic translation initiation factor eIF4E is an oncogene elevated in an estimated 30% of cancers. The traditional view is that eIF4E drives proliferation and survival by increasing t...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role...
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
Protein-protein interactions and allosterically regulated enzymes have been challenging but important targets for probe- and drug discovery. We and others have found that fragment-based lead...